Anti-CLC4M/ CLEC4M/ CD209L functional antibody
Anti-CLC4M/ CLEC4M/ CD209L functional antibody for cell culture, ELISA & in-vivo assay
Go to CLEC4M/CLEC4M products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE0093-Ab-1/ GM-Tg-hg-SE0093-Ab-2 | Anti-Human CLEC4M monoclonal antibody | Human |
GM-Tg-rg-SE0093-Ab-1/ GM-Tg-rg-SE0093-Ab-2 | Anti-Rat CLEC4M monoclonal antibody | Rat |
GM-Tg-mg-SE0093-Ab-1/ GM-Tg-mg-SE0093-Ab-2 | Anti-Mouse CLEC4M monoclonal antibody | Mouse |
GM-Tg-cynog-SE0093-Ab-1/ GM-Tg-cynog-SE0093-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CLEC4M monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE0093-Ab-1/ GM-Tg-felg-SE0093-Ab-2 | Anti-Feline CLEC4M monoclonal antibody | Feline |
GM-Tg-cang-SE0093-Ab-1/ GM-Tg-cang-SE0093-Ab-2 | Anti-Canine CLEC4M monoclonal antibody | Canine |
GM-Tg-bovg-SE0093-Ab-1/ GM-Tg-bovg-SE0093-Ab-2 | Anti-Bovine CLEC4M monoclonal antibody | Bovine |
GM-Tg-equg-SE0093-Ab-1/ GM-Tg-equg-SE0093-Ab-2 | Anti-Equine CLEC4M monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE0093-Ab-1/ GM-Tg-hg-SE0093-Ab-2; GM-Tg-rg-SE0093-Ab-1/ GM-Tg-rg-SE0093-Ab-2; GM-Tg-mg-SE0093-Ab-1/ GM-Tg-mg-SE0093-Ab-2; GM-Tg-cynog-SE0093-Ab-1/ GM-Tg-cynog-SE0093-Ab-2; GM-Tg-felg-SE0093-Ab-1/ GM-Tg-felg-SE0093-Ab-2; GM-Tg-cang-SE0093-Ab-1/ GM-Tg-cang-SE0093-Ab-2; GM-Tg-bovg-SE0093-Ab-1/ GM-Tg-bovg-SE0093-Ab-2; GM-Tg-equg-SE0093-Ab-1/ GM-Tg-equg-SE0093-Ab-2 |
Products Name | Anti-CLEC4M monoclonal antibody |
Format | mab |
Target Name | CLEC4M |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CLEC4M benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE0093-Ag-1 | Recombinant multi-species CLC4M/ CLEC4M/ CD209L protein |
ORF Viral Vector | pGMLPm001916 | mouse Cd209a Lentivirus plasmid |
ORF Viral Vector | vGMLPm001916 | mouse Cd209a Lentivirus particle |
Target information
Target ID | GM-SE0093 |
Target Name | CLEC4M |
Gene ID | 10332 |
Gene Symbol and Synonyms | CD209L,CD299,CLEC4M,DC-SIGN2,DC-SIGNR,DCSIGNR,HP10347,L-SIGN,LSIGN |
Uniprot Accession | Q9H2X3 |
Uniprot Entry Name | CLC4M_HUMAN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000104938 |
Target Classification | N/A |
The target: CLEC4M, gene name: CLEC4M, also named as CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, L-SIGN, LSIGN. This gene encodes a C-type lectin that functions in cell adhesion and pathogen recognition. This receptor recognizes a wide range of evolutionarily divergent pathogens with a large impact on public health, including tuberculosis mycobacteria, and viruses including Ebola, hepatitis C, HIV-1, influenza A, West Nile virus and the SARS-CoV acute respiratory syndrome coronavirus. The protein is organized into four distinct domains: a C-terminal carbohydrate recognition domain, a flexible tandem-repeat neck domain of variable length, a transmembrane region and an N-terminal cytoplasmic domain involved in internalization. This gene is closely related in terms of both sequence and function to a neighboring gene, CD209 (Gene ID: 30835), also known as DC-SIGN. The two genes differ in viral recognition and expression patterns, with this gene showing high expression in endothelial cells of the liver, lymph node and placenta. Polymorphisms in the tandem repeat neck domain are associated with resistance to SARS infection. [provided by RefSeq, May 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.